Endocrine Abstracts

Background and Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a diagnosis of inclusion relying on a set of metabolic risk factors and the presence of hepatic steatosisis; viscerl obesity, insulin resistance, type 2 diabetes (T2D) may often coexist in MAFLD patients. MAFLD is present in up to 80%f of T2D patients. Pioglidazone, a peroxisome proliferator-activated receptor agonist reduce hepatic/visceral fat (HVF) and improve necroinflammation in liver. Du...

Background and Aims: The metabolic-associated fatty liver disease (MAFLD) is a fatty liver accumulation with metabolic dysfunction (diabetes, overweight/obese, insulin-resistance), a definition more practical for identifying patients with fatty liver disease with high risk of disease progression. The triglyceride-glucose (TyG) index is a marker of insulin resistance. Long-term fasting plasma glucose (FPG) variability is associated with fatty liver content (FLC). Continuous glu...